SITC 2022 | Key updates in immunotherapies for melanoma

Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses recent advances in the field of immunotherapy for patients with melanoma. The Phase II SWOG S1801 trial (NCT03698019) of pembrolizumab resected stage III-IV melanoma demonstrated the superiority of neoadjuvant immunotherapy and novel T-cell receptor (TCR)-based adoptive therapies as well as monoclonal antibodies such as relatlimab are currently being assessed. Dr Davar additionally highlights tumor-infiltrating lymphocytes (TILs) including lifileucel and the expansion of CTLA4 inhibitors in other indications. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.